In this episode of the Innovations in Cardiology series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive quantification of coronary computed tomography angiography findings using an artificial intelligence algorithm that will enable an accurate quantification of coronary artery disease, including total coronary plaque volume and low attenuation plaque volume.
Findings showed that AI-guided quantative computational tomography quantification of coronary CTA lumen diameter stenosis and the noncalcified plaque volume were most predictive of MACE and added discriminative accuracy to the Diamond and Forrester predictive model. These atherosclerotic profiles as assessed by AI-QCT could guide the tailoring of anti atherosclerotic therapies or coronary interventional procedures to reduce the instance of cardiac events.
If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email managingeditor@ecrjournal.com.
Supported by an unrestricted educational grant from NOVO NORDISK A/S.
Dr Irene Martin de Miguel (Hospital General Universitario Gregorio Marañón, Madrid, Spain) joins us in this featured author episode to outline her recent review article, Atrial Fibrillation in Congenital Heart Disease. In this podcast, Dr de Miguel provides an overview of the current knowledge of AF in CHD, giving practical recommendations for your everyday practice.
Today's episode features co-hosts Dr Peter Ong and Dr Andreas Seitz (Robert-Bosch Hospital, Stuttgart, DE) who together summarise the main results from the TARGET FFR and DEFINE-FLOW trials that were presented at TCT Connect 2020 and published recently in ECR journal, in the context of the existing literature.
Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference.
